

Intermediate filament *Nestin* and the cell motility in cancer – a review

A.-M. SHI¹, Z.-Q. TAO², X. WANG³, Y.-Q. WANG⁴

¹School of Public Health of Nanjing Medical University, Nanjing, China

²Department of Science and Education, Xuzhou Central Hospital, Xuzhou, China

³Department of Thoracic Surgery, Xuzhou Central Hospital, Xuzhou, Jiangsu, China

⁴Department of Oncology Surgery, Xuzhou Central Hospital, Xuzhou, Jiangsu, China

Abstract. – The intermediate filaments (IFs) constitute the cytoskeleton which is a key feature of both prokaryotic and eukaryotic cells. The IFs are expressed throughout life and are involved in the regulation of cell differentiation, homeostasis, ageing and pathogenesis. The IFs not only provide structural integrity to the cell, but they are involved also in a range of cellular functions from organelle trafficking and cell migration to signaling transduction. The IFs are highly dynamic proteins, able to respond and adapt their network rapidly in response to intra- and extra-cellular cues. In cancer, these IFs play a crucial role with regard to cell invasion and cell motility. The present review article will enlighten information about important IF *Nestin* with regard to its role in cancer cell motility and invasion.

Key Words: Nestin, Cancer, Cell Motility, Invasion.

Introduction

The cytoskeleton consists of three distinct systems of proteins, fibers, all of which are engaged in essential functions for maintaining proper cell function, such as structural support, protein and organelle transport, cell cycle, cell motility, mechanosensing, intra- and extracellular signaling. The least known of the cytoskeletal systems, the intermediate filaments (IF), also comprises the largest protein family, coding for nearly 70 different proteins, each of which has distinct functions within the body. Within the IF family, there are two proteins of interest that are associated with cancer, *Nestin* and vimentin.

Nestin is a rather unique entity in that it is expressed briefly, in very specific cell types, such as in the brain, muscle, kidney and the central nervous system, at very specific times during a cell's life – during development and regeneration^{3,4}. This very specific timing and location of expression suggest that

Nestin has a very specific function in allowing cells to transition through these processes. *Nestin* is also found to be expressed in a wide array of cancer types, yet until now its function in cancer has remained a mystery. The leading cause of death in cancers is metastasis that ultimately leads to the not formation of the secondary tumors. Metastasis occurs when cells in the primary tumor acquire the ability to invade and migrate, a term known as malignant transformation. The intrinsic changes that undergoes during this transition is commonly known as epithelial to mesenchymal transition (EMT)⁵. During this transition, tumor cells are able to break out from the primary tumor and invade into the surrounding tissue. Some cells will invade into the network of blood and lymph vessels that a tumor attracts to feed itself (intravasation). From there they can travel to many distal sites in the body, such as the lungs, liver and bones. To begin the reverse process of colonizing the tissue to which they have travelled, the cells need to exit the blood or lymph vessels (extravasation) into the stroma. The metastasized tumor cells will then undergo reverse EMT, also known as mesenchymal to epithelial transition (MET), whereby they lose their motile abilities and reacquire some of the characteristics of the primary tumor. *Nestin* is most often expressed in intermediary stages of malignant transformation and is associated with cell migration and invasion. In the later sections, we will describe through understanding and details of *Nestin* about cancer cell invasion and metastasis.

Intermediate Filaments Structural Characteristics

The IFs are very elastic in nature and are able to resist shear stress without breaking⁶. Early studies suggested that one of the primary functions of the IFs was the maintenance of the basic structural

integrity of the cell. This elasticity and resistance to shear stress can be attributed to the hierarchical structure and specific structural changes during assembly of the IF filaments themselves⁷. IF proteins consist of an N-terminal “head” domain, a central rod and a C-terminal “tail” domain (Figure 1). IFs are assembled hierarchically. Dimers are formed through the interaction of two rod domains to form a coiled coil. The dimers assemble in an anti-parallel fashion to form tetramers which then assemble into unit length filaments (ULFs) composed of eight tetramers. The properties of IF filaments are not only conferred by their inherent structure and hierarchical assembly, the elastic properties of IFs are also regulated by ions. Support for the idea that the vimentin C-terminus is important for filament architecture come from a study showing that divalent cations, such as Ca^{2+} and Mg^{2+} , interacting with the last 11 amino acids on the vimentin tail promote stiffening of the filament network by crosslinking IF filaments⁷.

Intermediate Filaments Contribute to a Diverse Range of Pathologies

The identification of IF functions in the disease is often a result of their disease association. Some of the first identifications of intermediate filaments in disease were in cancer⁹. Common characteristics of many IF-related diseases arise from abnormalities with filament assembly, filament organization or aberrant regulation (PITRM, proteolytic degradation), all of which can have downstream effects on protein-protein interactions and cell signaling. In some cases, the IF in question is mutated. In other times, as with Hutchinson Progeria Syndrome (HGPS) and the keratin blistering diseases, the problem arises from non-altering mutations. Many disorders associated with type 4 IFs are characterized by abnormal protein aggregation arising from modification of PTMs and elevated protein expression. Understanding the role of the IFs in disease has facilitated the understanding of these proteins' function during homeostasis.

Nestin in Development and Angiogenesis

In recent years that a knock-out (KO) mouse has been developed for nestin. The studies by Mohseni et al¹⁰ and Yang et al¹¹ demonstrated that although nestin is not necessary for CNS development, it is important for peripheral motor function and development of the neuromuscular junction (NMJ). Nestin regulates acetylcholine

receptor (AChR) clustering at the NMJ. Nestin is transiently expressed during myogenesis and is understood to regulate the pace at which myogenesis occurs by acting as an inhibitor of Cdk5, a myogenesis promoting kinase. Nestin clearly has a role to play in angiogenesis during regeneration and pathology. It is also expressed in proliferating and metabolically active endothelium, independent of developmental and neoplastic processes.

The expression of nestin in angiogenesis may well be regulated by growth factors since mature endothelial cells cultured in the presence of growth factors had attenuated nestin expression. GFP is often coupled to nestin regulation as a reporter to study angiogenesis during tumor progression¹². Nestin is expressed in the adult angiogenic vasculature following myocardial infarction, especially in arterioles and malformations¹⁶. In the pituitary gland nestin is expressed during capillary neovascularization and is downregulated when pituitary infarcts transform to fibrotic tissue¹⁷. Compared with development, nestin expression in neovascularisation is transient and, as nestin is downregulated, vimentin expression is upregulated. While nestin appears to be expressed in proliferating endothelium in the adult, it is unclear whether this is a result of increased proliferation or whether it confers specific functions to the newly formed endothelial cells and vasculature¹⁸. Under shear flow conditions in the endothelium, nestin expression is decreased, which may reflect a need for cells to alter their proteome in order to resist this mechanical stress¹⁹.

Scaffolding and Cytoprotective Functions of Nestin

Nestin has a cytoprotective function in both neurons and podocytes in the kidney, and this is related to its interaction with and reciprocal regulation of Cdk5. Cdk5 regulates nestin filament organization²⁰ by phosphorylation at T316. Nestin sequesters Cdk5 and regulate its activity by modulating the Cdk5 activators p35/p25. During stress, such as oxidative stress or high glucose situations, nestin is degraded resulting in sensitization of the cells to Cdk5 pro-apoptotic activity²¹. Under stress conditions, Cdk5 is upregulated and acts upstream of caspase-3 to mediate apoptosis in high glucose treated podocytes. Nestin can attenuate this effect²² presumably by sequestering Cdk5. In vascular smooth muscle cells oxidative stress leads to nestin upregulation which inhibits apoptosis by Cdk5 sequestration²³. Cdk5

Table I. IF subtypes and associated diseases.

| Type | IF | Tissue | Disease |
|----------|--|--|--|
| I and II | Keratins | Skin, Stratified epithelia, e.g. nails, hair | Pancreatitis, Liver disease, skin and hair-related tissue fragility disorders e.g. Epidermolysis Bullosa (EB) |
| III | Desmin | Striated and smooth muscle | Myopathies, Cardiomyopathy |
| | Glial fibrillary acidic protein (GFAP) | CNS, peripheral nervous system (PNS) | Alexander Disease (AxD), Neurodegenerative diseases inc. Alzheimer's, Parkinson's (PD), Amyotrophic lateral sclerosis (ALS) |
| | Peripherin | CNS, peripheral nervous system (PNS) | Acute motor neuron degeneration |
| IV | Nestin | CNS, PNS, heart, kidney, muscle | Cancer, AD |
| V | Lamins | Nuclear lamina | Lipo and muscular dystrophies, CMT, cardiomyopathy, Adult-onset autosomal dominant leukodystrophy (ADLD) and premature ageing diseases e.g. HGPS |

is only released once a threshold has been reached that removes the inhibitory scaffold by phosphorylation-dependent reorganization through degradation. While the interactions with Cdk5 are the best characterized so far, other phosphorylation sites have been identified on nestin which will require further study²⁴.

Nestin in Regeneration

The fact that nestin expression rarely persists in fully repaired tissue lends support to the idea that nestin plays a functional role in tissue repair. Nestin expression appears to be primarily in angiogenic structures and progenitor cells recruited to the regenerative site. During regeneration, nestin expression is induced by similar factors to those involved in differentiation, suggesting that regeneration could be used as a model to study nestin protein expression and function and vice versa. In myoblasts, nestin regulates DNA synthesis and proliferation which accelerates the healing process following ischemia²⁵. In the kidney, nestin has a slightly different function. In proximal tubule cells, nestin is transiently upregulated in response to hypoxia and TGF β and regulates the migration of immature renal cells to the site regenerating regeneration²⁶. Nestin is also upregulated by TGF β and PDGF in damaged mesangial cells, which surround the glomerulus. Nestin was shown to regulate their proliferation, but not their migration highlighting the cell-type specificity of

nestin function. Nestin is also re-expressed in the pancreas, skin, retina and teeth following trauma. However, its function in these regeneration processes is poorly characterized.

Nestin in Cancer

Nestin has been identified in a number of cancers including osteosarcoma, prostate, breast testicular cancer, ovarian, skin cancers, gastrointestinal tract cancers, lung cancer, pancreatic cancer, anaplastic thyroid carcinoma, angiosarcoma, glioma and other CNS tumors to name a few²⁷. During development nestin is considered as a progenitor cell marker, it is also a marker for cells in early neoplastic stages and during angiogenesis. The mechanisms that regulate nestin expression during development and regeneration may also regulate nestin expression during transformation²⁸. Several studies investigate the correlation of nestin expression in tumors with various clinical outcomes, such as prognosis, tumor grade, metastasis, recurrence and survival (Table I).

In some cases, nestin expression did correlate with worse clinical outcomes, such as worse tumor grade or metastasis. However, this was not always associated with decreased patient survival²⁹. This variation could be due to study protocol differences, as well as a reflection of the potential complexity of nestin's function in cancer. Much of the correlative data should be treated with care until there is a better understanding of how nestin functions in cancer.




Figure 1. Intermediate filaments.

In vivo nestin expression may come from the tumor and metastasis itself, but in some cases it appears to be a response by the surrounding tissue to the “injury” caused by the tumor³⁰. Nestin-expressing progenitor cells can be recruited from the stroma to the tumor itself, either from the host or by the tumor secreted growth factors. Nestin-positive host cells recruited by tumors, such as gliomas, can both augment and inhibit functions such as tumor growth through angiogenesis and dissemination from the primary tumor³¹. In other cases, the nestin expression comes from local upregulation in the tissue proximal to the tumor³². This reflects nestin’s role in regeneration as opposed to a detrimental pathological role that is critical in these cases. The different frequency between the cancer cells and the tumor microenvironment.

Conclusions

It is quite evident from the above literature that nestin plays a crucial role in cancer cell invasion and motility. The details provided shall help to further work on new drugs to target specifically

various key attributes of this molecule to efficiently manage the critical process of cell invasion. This shall definitely allow efficient management of cancer cell metastasis, the real cause of mortality behind cancer.

Conflicts of interest

The authors declare no conflicts of interest.

References

- 1) FLETCHER DA, MULLINS RD. Cell mechanics and the cytoskeleton. *Nature* 2010; 463: 485-492.
- 2) ROUX A, GILBERT S, LORANGER A, MARCEAU N. Impact of keratin intermediate filaments on insulin-mediated glucose metabolism regulation in the liver and disease association. *FASEB J* 2016; 30: 491-502.
- 3) CHABOT A, HERTIG V, BOSCHER E, NGUYEN QT, BOMIN B, CHEBLI J, BISSONNETTE E, VILLENEUVE L, BROCHIERO E, DUPUIS J, CALDERONE A. Endothelial and epithelial cell transition to a mesenchymal phenotype was delineated by nestin expression. *J Cell Physiol* 2016; 231: 1601-1610.
- 4) HE QZ, LUO XZ, ZHOU Q, WANG K, LI SX, LI Y, ZHU HT, DUAN T. Expression of nestin in ovarian se-

- rous cancer and its clinicopathologic significance. *Eur Rev Med Pharmacol Sci* 2013;17:2896-2901.
- 5) SHUKLA P, VOGL C, WALLNER B, RIGLER D, MÜLLER M, MACHO-MASCHLER S. High-throughput mRNA and miRNA profiling of epithelial-mesenchymal transition in MDCK cells. *BMC Genomics* 2015; 16: 944.
 - 6) WAGNER OI, RAMMENSEE S, KORDE N, WEN O, LETERRIER JF, JANMEY PA. Softness, strength and self-repair in intermediate filament networks. *Exp. Cell Res* 2007; 313: 2228-2235.
 - 7) QIN Z, KREPLAK L, BUEHLER MJ. Hierarchical structure controls nanomechanical properties of vimentin intermediate filaments. *PLoS One* 2009; 4: e7294.
 - 8) LIN YC, BROEDERSZ CP, ROWAT AC, WEDIG T, HERRMANN H, MACKINTOSH FC, WEITZ DA. Divalent cations crosslink vimentin intermediate filament tail domains to regulate network mechanics. *J Mol Biol* 2010; 399: 637-644.
 - 9) MIETTINEN M, LEHTO VP, BADLEY RA, VIRTANEN I. Expression of intermediate filaments in soft-tissue sarcomas. *Int J Cancer* 1982; 30: 541-546.
 - 10) MOHSENI P, SUNG HK, MURPHY AJ, LALIBERTE CL, PALLARI HM. Nestin is not essential for development of the CNS but required for dispersion of acetylcholine receptor clusters at the area of neuromuscular junctions. *J. Neurosci* 2011; 31: 11547-11552.
 - 11) YANG J, DOMINGUEZ B, DE WINTER F, GOULD TW, ERICSSON JE, LEE KF. Nestin negatively regulates synaptic differentiation of the neuromuscular synapse. *Nat Neurosci* 2011; 14: 324-330.
 - 12) PALLARI HM, LINDQVIST J, TORVALDSON E, FERRARI HE T, SAHLGREN C, ERICSSON JE. Nestin as a regulator of Cdk5 in differentiating myoblasts. *Mol Biol Cell* 2011; 22: 1539- 1549.
 - 13) MOKRÝ J, KARBANOVÁ J, CÍZKOVÁ J, SOUKUP P, BUCHÁNEK J, FILIP S, KOLÁŘ Z. Expression of intermediate filament nestin in blood vessels of rat and human tissues. *Acta Medica* 2008; 51: 105-110.
 - 14) SUZUKI S, NAMIKI J, HIBATA S, MASUDA Y, OKANO H. The neural stem/progenitor cell marker nestin is expressed in proliferative endothelial cells, but not in mature vasculature. *J Histochem Cytochem* 2010; 58: 721-730.
 - 15) AMONTE BOUVET M, LI L, TSENG Y, MOOSSA AR, KATSUOKA T, HOFFMAN RM. Visualization of nascent tumor angiogenesis in lung and liver metastasis by differential dual-color fluorescence imaging in nestin-GFP mice. *Clin Exp Metastasis* 2006; 23: 81-87.
 - 16) OHMIZU M, YAMAMOTO T, TOSAKA M, IMAI H, HOYA K, TAKEUCHI T, SASAKI T, NISHIMOTO N. Nestin expression in vascular malformations: a novel marker for proliferative endothelium. *Neurol Med Chir* 2006; 46: 111-117.
 - 17) KISSMANN ROVACS K, CUSIMANO MD, HORVATH E, BELL CD, ROTUNDO F, SCHEITHAUER BW. Immunohistochemical expression of nestin in adenohypophysial vessels during development of pituitary infarction. *Neurosurg* 2008; 108: 118-123.
 - 18) BRYCHTOVA S, FIURASKOVA M, HLOBILKOVA A, BRYCHTA T, HIRNAK J. Nestin expression in cutaneous melanomas and melanocytic nevi. *J Cutan Pathol* 2007; 34: 370-375.
 - 19) SUGAWARA K, KURIHARA H, NEGISHI M, SAITO N, NAKAZATO Y, SASAKI T, TAKEUCHI T. Nestin as a marker for proliferative endothelium in gliomas. *Neuroscience* 2002; 82: 345-351.
 - 20) DE THONEL A, FERRARIS SE, PALLARI HM, ERICSSON SY, KOCHIN V, HOSOKAWA T, HISANAGA S, SAHLGREN C, ERICSSON JE. Protein kinase Czeta regulates Cdk5/p35 signaling during myogenesis. *Mol Biol Cell* 2010; 21: 1432-1434.
 - 21) LIU W, ZHANG Y, HAO J, LIU Q, ZHAO S, ZHANG H. Nestin protects mouse podocytes against glucose-induced apoptosis by a Cdk5-dependent mechanism. *J Cell Biochem* 2010; 113: 3186-3196.
 - 22) LIU W, ZHANG Y, LIU Q, SHI Y, ZHANG H, DUAN H. The expression of intermediate filament protein nestin and its association with Cdk5-dependent kinase 5 in the afferent arterioli of rats with diabetic nephropathy. *Int J Mol Med* 2013; 345: 470-477.
 - 23) HUANG YL, WU CM, CHEN Y, WU GC, LEE H, JIANG MJ, YANG HY. Nestin serves as a prosurvival determinant that is linked to the cytoprotective effect of epidermal growth factor in rat vascular smooth muscle cells. *J Biochem* 2009; 146: 307-315.
 - 24) NAMIKI J, SUZUKI S, MASUDA T, ISHIHAMA Y, OKANO H. Nestin protein is phosphorylated in adult neural stem/progenitor cells and not endothelial progenitor cells. *Stem Cells Int* 2012; 2012: 430138.
 - 25) BÉGUIN PC, GOSSELIN H, MAMARBACHI M, CALDERONE A. Nestin expression is lost in ventricular fibroblasts during postnatal development of the rat heart and is expressed in scar myofibroblasts. *J Cell Physiol* 2012; 227: 813-820.
 - 26) WEN D, NI L, YOU L, ZHANG L, GU Y, HAO CM, CHEN J. Upregulation of nestin in proximal tubules may participate in cell migration during renal repair. *Am J Physiol Renal Physiol* 2012; 303: F1534- 44.
 - 27) ISHIWATA T, MATSUDA Y, NAITO Z. Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. *World J Gastroenterol* 2011; 17: 409-418.
 - 28) LEACH SD. Epithelial differentiation in pancreatic development and neoplasia: new niches for nestin and Notch. *J Clin Gastroenterol* 2005; 39: S78-82.
 - 29) ZAMBO I, HERMANOVA M, ADAMKOVA KRAKOROVA D, MUDRY P, ZITTEBART K, KYR M, VESELY K, STERBA J, VESELSKA R. Nestin expression in high-grade osteosarcomas and its clinical significance. *Oncol Rep* 2012; 27: 1592-1598.
 - 30) IDOATE MA, DÍEZ VALLE R, ECHEVESTE J, TEJADA S. Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence. *Neuropathology* 2011; 31: 575-582.
 - 31) NAJBAUER J, HUSZTHY PC, BARISH ME, GARCIA E, METZ MZ, MYERS SM, GUTOVA M, FRANK RT, MILETIC H, KENDALL SE. Cellular host responses to gliomas. *PLoS One* 2012; 7: e35150.
 - 32) PIRAS F, PERRA MT, MURTAS D, MINERBA L, FLORIS C, MAXIA C, DEMURTAS P, UGALDE J, RIBATTI D, SIRIGU P. The stem cell marker nestin predicts poor prognosis in human melanoma. *Oncol Rep* 2010; 23: 17-24.